These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28948518)

  • 1. Molecular Subgroups of Glioblastoma- an Assessment by Immunohistochemical Markers.
    Nagy Á; Garzuly F; Padányi G; Szűcs I; Feldmann Á; Murnyák B; Hortobágyi T; Kálmán B
    Pathol Oncol Res; 2019 Jan; 25(1):21-31. PubMed ID: 28948518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simplified integrated molecular and immunohistochemistry-based algorithm allows high accuracy prediction of glioblastoma transcriptional subtypes.
    Orzan F; Pagani F; Cominelli M; Triggiani L; Calza S; De Bacco F; Medicina D; Balzarini P; Panciani PP; Liserre R; Buglione M; Fontanella MM; Medico E; Galli R; Isella C; Boccaccio C; Poliani PL;
    Lab Invest; 2020 Oct; 100(10):1330-1344. PubMed ID: 32404931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.
    Murata H; Yoshimoto K; Hatae R; Akagi Y; Mizoguchi M; Hata N; Kuga D; Nakamizo A; Amano T; Sayama T; Iihara K
    J Neurooncol; 2015 Oct; 125(1):33-41. PubMed ID: 26272600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular heterogeneity of glioblastomas: does location matter?
    Denicolaï E; Tabouret E; Colin C; Metellus P; Nanni I; Boucard C; Tchoghandjian A; Meyronet D; Baeza-Kallee N; Chinot O; Figarella-Branger D
    Oncotarget; 2016 Jan; 7(1):902-13. PubMed ID: 26637806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
    Carrato C; Alameda F; Esteve-Codina A; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Lopez-Martos R; Barco SD; Ribalta T; Capellades J; Puig J; Gallego O; Mesia C; Muñoz-Marmol AM; Archilla I; Arumí M; Blanc JM; Bellosillo B; Menendez S; Esteve A; Bagué S; Hernandez A; Craven-Bartle J; Fuentes R; Vidal N; Aldecoa I; Iglesia N; Balana C
    Clin Cancer Res; 2020 Dec; 26(24):6600-6609. PubMed ID: 32998960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma.
    Zhang JX; Zhang J; Yan W; Wang YY; Han L; Yue X; Liu N; You YP; Jiang T; Pu PY; Kang CS
    Neuro Oncol; 2013 Mar; 15(3):279-89. PubMed ID: 23295773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA sequencing and Immunohistochemistry Reveal
    Esteve-Codina A; Alameda F; Carrato C; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Dabad M; Tortosa A; Del Barco S; Capellades J; Puig J; Gallego O; Pujol T; Oleaga L; Gil-Gil M; de Quintana-Schmidt C; Valduvieco I; Martinez-Cardús A; Bellosillo B; Muñoz-Marmol AM; Esteve A; Domenech M; Camins A; Craven-Bartle J; Villa S; Marruecos J; Domenech S; de la Iglesia N; Balana C
    Clin Cancer Res; 2021 Jan; 27(2):645-655. PubMed ID: 33106291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
    Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
    Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?
    Vasaikar S; Tsipras G; Landázuri N; Costa H; Wilhelmi V; Scicluna P; Cui HL; Mohammad AA; Davoudi B; Shang M; Ananthaseshan S; Strååt K; Stragliotto G; Rahbar A; Wong KT; Tegner J; Yaiw KC; Söderberg-Naucler C
    BMC Cancer; 2018 Feb; 18(1):154. PubMed ID: 29409474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI study identifies three subtypes of glioblastoma.
    Brower V
    Lancet Oncol; 2015 Oct; 16(13):e484. PubMed ID: 26365415
    [No Abstract]   [Full Text] [Related]  

  • 11. Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma.
    Park J; Shim JK; Yoon SJ; Kim SH; Chang JH; Kang SG
    Sci Rep; 2019 Jul; 9(1):10555. PubMed ID: 31332251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical markers for prognosis of cerebral glioblastomas.
    Korshunov A; Golanov A; Sycheva R
    J Neurooncol; 2002 Jul; 58(3):217-36. PubMed ID: 12187957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20.
    Marucci G; Morandi L; Magrini E; Farnedi A; Franceschi E; Miglio R; Calò D; Pession A; Foschini MP; Eusebi V
    Virchows Arch; 2008 Dec; 453(6):599-609. PubMed ID: 18953566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.
    Jungk C; Mock A; Exner J; Geisenberger C; Warta R; Capper D; Abdollahi A; Friauf S; Lahrmann B; Grabe N; Beckhove P; von Deimling A; Unterberg A; Herold-Mende C
    BMC Med; 2016 Oct; 14(1):170. PubMed ID: 27782828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal tissue content impact on the GBM molecular classification.
    Madurga R; García-Romero N; Jiménez B; Collazo A; Pérez-Rodríguez F; Hernández-Laín A; Fernández-Carballal C; Prat-Acín R; Zanin M; Menasalvas E; Ayuso-Sacido Á
    Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32632447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative proteomics reveals the novel co-expression signatures in early brain development for prognosis of glioblastoma multiforme.
    Yu X; Feng L; Liu D; Zhang L; Wu B; Jiang W; Han Z; Cheng S
    Oncotarget; 2016 Mar; 7(12):14161-71. PubMed ID: 26895104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
    Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
    Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
    Zhang J; Xiao X; Zhang X; Hua W
    J Mol Neurosci; 2020 May; 70(5):738-750. PubMed ID: 32006162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.